Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial)

Rosaura Casas¹ · Fabrícia Dietrich¹ · Sara Puente-Marín¹ · Hugo Barcenilla¹ · Beatriz Tavira¹ · Jeannette Wahlberg² · Peter Achenbach³ · Johnny Ludvigsson¹⁴∗

Received: 23 October 2021 / Accepted: 12 January 2022 © The Author(s) 2022

Abstract

Aim To evaluate the long-term effect of intra-lymphatic administration of GAD-alum and a booster dose 2.5 years after the first intervention (DIAGNODE Extension study) in patients with recent-onset type 1 diabetes.

Methods DIAGNODE-1: Samples were collected from 12 patients after 30 months who had received 3 injections of 4 μg GAD-alum into a lymph node with one-month interval. DIAGNODE Extension study: First in human, a fourth booster dose of autoantigen (GAD-alum) was given to 3 patients at 31.5 months, who were followed for another 12 months. C-peptide was measured during mixed meal tolerance tests (MMTTs). GADA, IA-2A, GADA subclasses, GAD65-induced cytokines, PBMCs proliferation and T cells markers were analyzed.

Results After 30-month treatment, efficacy was still seen in 8/12 patients (good responders, GR). Partial remission (IDAA1c < 9) had decreased compared to 15 months, but did not differ from baseline, and HbA1c remained stable. GAD₆₅-specific immune responses induced by the treatment started to wane after 30 months, and most changes observed at 15 months were undetectable. GADA subclasses IgG2, IgG3 and IgG4 were predominant in the GR along with IgG1. A fourth intra-lymphatic GAD-alum dose to three patients after 31.5 months gave no adverse events. In all three patients, C-peptide seemed to increase the first 6 months, and thereafter, C-peptide, HbA1c, insulin requirement and IDAA1c remained stable.

Conclusion The effect of intra-lymphatic injections of GAD-alum had decreased after 30 months. Good responders showed a specific immune response. Administration of a fourth booster dose after 31.5 months was safe, and there was no decline in C-peptide observed during the 12-month follow-up.

Keywords Autoantigen · Immunotherapy · GAD-alum · Intra-lymphatic · Type 1 diabetes · Booster dose

Managed by Antonio Secchi.

Rosaura Casas and Fabrícia Dietrich have equally contributed to this work.

Johnny Ludvigsson
johnny.ludvigsson@liu.se

1 Division of Pediatrics, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden

2 Department of Endocrinology and Department of Medical and Health Sciences and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden

3 Institute of Diabetes Research, School of Medicine, Forschergruppe Diabetes, Helmholtz Zentrum München, Technical University of Munich, Munich, Germany

4 Division of Pediatrics, Department of Biomedical and Clinical Sciences, Faculty of Medicine Health Sciences and Crown Princess, Victoria Children’s Hospital, Linköping University, 58185 Linköping, SE, Sweden

Published online: 31 January 2022
Abbreviations

GADA  Glutamic acid decarboxylase autoantibodies
GAD-alum  Glutamic acid decarboxylase formulated with aluminum hydroxide
IDAA1c  Insulin dose-adjusted glycated hemoglobin A1c
LN  Lymph node
MMTT  Mixed meal tolerance test
PBMC  Peripheral blood mononuclear cell
SC  Subcutaneous
Th  T helper
GR  Good responders
PR  Poor responders

Introduction

Despite the use of modern devices and drugs, treatment of type 1 diabetes is heavy and the disease cause complications and increased mortality [1, 2]. Immune interventions to preserve residual beta cell function have been tried for several decades [3], but the effect has been limited and transient, and some have been accompanied by serious risks and adverse events [4–12]. Subcutaneous (sc) administration of glutamic acid decarboxylase (GAD) 65 formulated with aluminum hydroxide (GAD-alum) has shown to be easy and safe, but the clinical results have been inconclusive [13–15], even though a meta-analyses showed very high probability that the treatment is efficacious [16]. The treatment needs to be improved.

It is known that intra-lymphatic administration of antigens can maximize immunogenicity and hence the efficacy of several vaccines [17, 18]. Thus, in an attempt to render the presentation of GAD65 more efficient, GAD-alum was injected into an inguinal lymph node in 12 individuals with recent-onset type 1 diabetes in an open-label clinical trial (DIAGNODE-1), being the first-in-human trial with autoantigen given intra-lymphatic. Results from the 6 and 15-month follow-up showed that the treatment was safe, but the clinical results have been inconclusive [13–15], even though a meta-analyses showed very high probability that the treatment is efficacious [16]. The treatment needs to be improved.

Now we ask the question how long term the immunological effect will be after three doses of intra-lymphatic GAD-alum injections, and therefore, a follow-up of DIAGNODE-1 has been conducted 30 months after the treatment was initiated. With the hypothesis that the effect is declining, we had already in the end of DIAGNODE-1 applied for permission to study whether the addition of a late intra-lymphatic booster dose of GAD-alum could prolong the efficacy and immune response. A fourth dose as a booster given 2.5 years after the initial treatment was allowed in three adult patients who had earlier participated in DIAGNODE-1, constituting the DIAGNODE Extension study. We are aware of the very low number of patients investigated, but understand that this is a first-in-human trial when the treatment either might lead to deleterious effects on both beta cell function and immune system, with risk for adverse events, or show to have positive effects without adverse events. The result of this study may have great consequences for future trials with autoantigen therapy.

Research design and methods

Study design and participants

In DIAGNODE-1 as described earlier [21], 12 individuals (4 females and 8 males), aged 12–24 years with type 1 diabetes < 6 months from diagnosis, received a primary injection of 4 μg of GAD-alum (Diamyd Medical, Stockholm) into an inguinal lymph node administrated by help of ultrasound technique, followed by two booster injections of 4 μg each with one-month interval. In parallel, patients also received vitamin D (calciferol) in oral solution (2000 U/d) for 4 months, starting 1 month prior to first GAD-alum injection. The participants were eligible if fasting C-peptide ≥ 0.12 nmol/L and GAD65 antibody levels (GADA) > 63.2 RU [21].

In the first-in-human DIAGNODE Extension study, the Research Ethics Board and the Swedish Medical Product Agency allowed the inclusion of three pilot adult patients who just ended the DIAGNODE-1 trial. They received a fourth injection of GAD-alum (4 μg) into an inguinal lymph node 1.5 months after the 30-month follow-up of DIAGNODE-1, that is, 31.5 months after the start of their first treatment in DIAGNODE-1, in combination with oral vitamin D intake one month before and one month after the fourth intra-lymphatic GAD-alum injection. The patients were followed with mixed meal tolerance tests (MMT Ts) [25] and immunological studies for 12 months (NCT02352974).

Laboratory test

Laboratory analyses were performed at Linköping University, Sweden. Blood and serum samples from all the
DIAGNODE-1 participants were collected at baseline and after 15, 30 months. Additionally, samples from the three patients in DIAGNODE Extension were collected at 31.5, 33.5, 36.5 and 42.5 months. Samples were drawn during the morning hours, and peripheral blood mononuclear cells (PBMCs) were isolated within 24 h using Leucosep (Greiner Bio One) according to the manufacturer’s instructions.

Analysis of serum C-peptide was performed using a solid-phase two-sided enzyme immunoassay (Mercodia, Uppsala). Results for each assay were validated with the inclusion of a Diabetes Antigen Control Human (Low/High) (Mercodia, Uppsala, Sweden). The assay is calibrated against the international reference reagent for C-peptide IRR C-peptide 84/510. Inter- and intra-assay variations were 6.6% and 3.5%, respectively.

Serum antibodies and IgG subclasses

Serum GAD autoantibodies (GADA) were estimated in duplicate by means of a radio-binding assay, using 35S-labeled recombinant human GAD65 (rhGAD65) as previously described [26]. Sepharose protein A was used to separate free from antibody-bound labeled GAD65.

GADA IgG1, IgG2, IgG3 and IgG4 subclasses were measured by radio-binding assays [27] using IgG subclass-specific biotin-labeled mouse–antihuman monoclonal antibodies bound on streptavidin sepharose high-performance beads (GE Healthcare Life Sciences, Freiburg, Germany) [20]. Results were expressed as delta cpm (IgG subclass-specific cpm—anti-rat IgM cpm) and converted to arbitrary units (AUs) proportional to the GADA IgG subclass-specific delta cpm of a local standard serum.

Lymphocyte proliferation assay

Proliferative responses were analyzed in PBMCs cultured in triplicates in medium alone (AIM-V medium with β-mercaptoethanol), in the presence of 5 μg/mL rhGAD65 (Diamyd Medical, Stockholm, Sweden) or with CD3/CD28 beads (Gibco, Life Technologies AS, Oslo, Norway). After 3 days, cells were incubated with 0.2 μCi of [3H] thymidine/well (PerkinElmer) for 18 h and thereafter harvested. Proliferation was expressed as stimulation index (SI), calculated as the mean cpm of cells cultured triplicates in the presence of stimulus divided by the mean cpm of cells with medium alone.

Cytokine secretion assay

PBMCs were cultured for 7 days in the presence of 5 μg/mL rhGAD65 or in medium alone at 37 °C in 5% CO2, as previously described [28]. The cytokines IL-2, IL-5, IL-10, IL-13, IL-17, tumor necrosis factor (TNF-α) and interferon (IFN-γ) were measured in cell culture supernatants using Bio-Plex Pro Cytokine Panel (Bio-Rad, Hercules, CA, USA) according to the manufacturer’s instructions. Data were collected using the Luminex 200™ (Luminex xMAPTM Corporation, Austin, TX USA). The antigen-induced cytokine secretion level was calculated by subtracting the spontaneous secretion (i.e. secretion from PBMCs cultured in medium alone) from the one following stimulation with GAD65.

Flow cytometry

PBMCs were washed in PBS containing 0.1% BSA and subsequently stained with Alexa-700-conjugated anti-CD3 (clone UCHT1, BD Biosciences), Pacific Blue-conjugated anti-CD4 (clone RPA-T4, BD Biosciences), allophycocyanin (APC)-H7-conjugated anti-CD8 (clone SK1, BD Biosciences), PerCP-Cys5.5-conjugated anti-CD45RA (clone HI100, BD Biosciences), phycoerythrin (PE)-conjugated anti-CCR7 (clone G043H7, Biolegend), FITC-conjugated anti-CD127 (clone eBioRDR5, eBioscience) and PE-Cy7-conjugated anti-CD25 (clone BC96, eBioscience). Then, cells were fixed and permeabilized using FOXP3 staining buffer set (eBioscience), according to the manufacturer’s instructions. Cells were then stained with APC-conjugated anti-FOX3 (clone PCH101, eBiosciences) and acquired on a FACS Aria III (BD Biosciences) running FACS Diva version 8 software (Becton Dickinson). Data were analyzed using Kaluza version 1.3 (Beckman Coulter).

T cell differentiation was determined according to the expression of CD45RA and CCR7 as naive (TN, CD45RA + CCR7 +), central memory (TCM, CD45RA–CCR7 +) and effector memory (TEM, CD45RA–CCR7– and CD45RA + CCR7–).

Regulatory T cells were defined as CD25 + CD127–FOX3+ CD4+ T cells. Further analysis of regulatory T cell subpopulations was based on the expression of FOXP3 and CD45RA as resting (rTreg, FOXP3low + CD45RA +), activated (aTreg, FOXP3high CD45RA–) and non-suppressive (nsTregFOXP3lowCD45RA–) regulatory T cells.

Induction of activated T cells was calculated as the difference between the percentage of CD25 + CD127–FOX3+ CD4+ T cells in GAD65-stimulated cultures and the percentage of CD25 + CD127+ T cells in medium alone.

Clinical evaluation

In addition to C-peptide measurements during 2-h mixed meal tolerance test [25], we also used insulin dose U/kg body weight, 24 h as well as HbA1c. Insulin dose and HbA1c were combined to calculate insulin dose-adjusted A1c according to Mortensen et al. [23] whose results suggested the definition of an insulin dose-adjusted A1c (IDAA1c) as A1c
(percent) + [4 × insulin dose (units per kilogram per 24 h)]. A calculated IDAA1c ≤ 9 corresponding to a predicted stimulated C-peptide > 300 pmol/l was used to define partial remission. To investigate immune response in relation to C-peptide preservation, patients were stratified into good responders (GR, n = 8; no loss of fasting C-peptide and loss of C-peptide AUC < 30%) and poor responders (PR, n = 4; decreasing fasting C-peptide and loss of C-peptide AUC ≥ 30%) according to C-peptide preservation and clinical response at 15 months, with cutoff for AUC 55% at 30 months.

**Statistical analysis**

Variables that followed a normal distribution (clinical data) were presented as mean. Differences between groups were calculated using Student t-test, and differences within groups were calculated by paired t test. Variables that follow a non-normal distribution (immune data), were presented as median and nonparametric tests were applied. Differences between groups were calculated using Mann–Whitney test, and for the calculation of differences within groups, Wilcoxon test was applied. A probability level of < 0.05 was considered statistically significant. Calculations were performed using GraphPad Prism 8.0.1 for Windows (GraphPad Software, La Jolla, CA, USA).

**Results**

**Clinical response at 30 months**

Fasting and stimulated C-peptide, measured as the area under the curve (AUC), decreased after 30 months compared to both baseline and 15-month levels. Insulin requirement was higher than at 15 months, while HbA1c remained stable. IDAA1c decreased compared to 15 months, but did not differ from baseline (Fig. 1A).

Fasting and stimulated C-peptide (AUC) were significantly higher in GR patients (n = 8), who also had lower insulin requirement and IDAA1c compared to PR patients (n = 4) (Fig. 1B, Supplementary Table S1).

**Immune responses at 30 months**

GADA levels increased, more so in GR patients, through the study and were higher at 30 months than after 15 months. Analysis of GADA IgG subclasses showed that the levels of IgG1, IgG2, IgG3 and IgG4 remained higher at 30 months than baseline. Comparison of GADA between GR and PR patients showed that the increase observed in the whole cohort was due to higher levels in GR individuals, while the same difference was not observed in PR subjects (Fig. 2A).

Distribution of IgG subclasses, calculated as frequency of each subclass with respect to the combined sum of the AUs of all subclasses in each sample, was similar at 30 months to baseline distribution in the whole group. However, stratification of the samples into GR and PR showed a greater proportion of IgG2, IgG3 and IgG4 in GR individuals, while IgG1 was the predominant subclass especially in the PR individuals (Fig. 2B).

GAD$_{65}$-induced cytokine secretion observed at earlier visits waned after 30 months, and almost all analyzed cytokines were undetectable, with the exception of IL-13 which continued to increase at 30 months compared to both baseline and 15 months (Fig. 2C, Supplementary Fig S1). The reduction of GAD$_{65}$-induced proliferation observed at 15 months remained stable after 30 months, and proliferation was almost undetectable in all patients (Fig. 2D).

Analysis of T cell differentiation revealed that only CD4 + Tcm cells remained significantly reduced at 30 months, while Tcm and Tem fractions of CD8 + T cells did not differ significantly between baseline and 30 months (Fig. 2E). The percentage of regulatory T cell and their subpopulations did not change throughout the study (Supplementary Fig S1). GAD$_{65}$ stimulation did not induce a significant change in activated CD4 + T cells. However, the induction of activated CD8 + T cells increased significantly from 15 to 30 months reaching similar levels as baseline (Supplementary Fig S1). When patients were stratified into GR and PR, a significant increase in GAD$_{65}$-induced activated CD4 + T cells from baseline to 30 months was observed in the GR group (Fig. 2F). Comparison of GAD$_{65}$-induced activated cells between the groups revealed a significantly higher fold change from baseline to 30 months of both CD4 + and CD8 + T cells in GR patients (Fig. 2F).

**Clinical and immune responses after the late booster injection of GAD-alum (DIAGNODE Extension)**

Administration of a fourth injection of GAD-alum as a late booster dose was safe, and no adverse events were observed. Follow-up of the patients 6 and 12 months after the start of DIAGNODE extension study showed that C-peptide secretion seemed to increase in all three patients after 6 months and then remained at a stable level at 12-month follow-up, that is, still 42.5 months from the start of DIAGNODE-1. HbA1c, insulin requirement and IDAA1c seemed to stabilize after the late booster dose (Fig. 3A, Supplementary Table S2).

Analysis of the individual immunological responses showed that GADA did not further increase in subjects 5 and 7, while it was enhanced in patient 6. GADA subclass distribution seemed to be unaffected in the three individuals.
Fig. 1  A Change from baseline to 30 months of fasting and stimulated C-peptide (AUC), HbA1c, IDAAC and insulin dose in type 1 diabetes patients (n = 12) receiving GAD-alum injections into the lymph node. Values are expressed as mean percentage. Error bars indicate 95% CI. Differences between time points were determined by paired t-Test. B Change from baseline of fasting and stimulated C-peptide (AUC), HbA1c, IDAAC and insulin dose in the patients stratified into good responders (GR, n = 8) and poor responders (PR, n = 4) according to their C-peptide preservation at 30 months. Error bars indicate 95% CI. Wilcoxon test was applied to calculate differences between time points and Mann–Whitney test to calculate differences between groups
Secretion of GAD65-induced cytokines was boosted in subjects 5 and 7, but the same clear increase was not observed in subject 6 (Fig. 3C, Supplementary Fig S2). GAD65-induced proliferation waned in patients 5 and 7, but increased in patient 6 (Fig. 3D). Analysis of T cell activation by GAD65 stimulation revealed that all three individuals reduced the activation of CD8+ T cells after the booster injection, although patient 7 maintained higher levels than baseline at the start of DIAGNODE-1 (Supplementary Fig S2).

Conclusions

Follow-up of the patients in DIAGNODE-1 showed that C-peptide preservation observed after 6 and 15 months [21] had declined at 30 months as a mean for the total group, but remained good in 8/12 patients (good responders). Insulin requirement had increased while HbAc1 remained stable. IDAA1c decreased compared to 15 months, but was still 30 months after the treatment as good as at baseline, when the patients had less than 6-month duration of type 1 diabetes.
diabetes. The gradual decrease in the clinical efficacy was accompanied by a decrease in the immune response. Thus, GAD65-specific immune responses induced by the treatment had weaned, and most changes observed at 6 and 15 months \([19–21]\) were undetectable. An important exception was the increased GAD65-induced secretion of IL-13, a main Th-2 effector cytokine well known for exerting anti-inflammatory activity, stimulate T helper cell differentiation and antibody isotype switching in B cells [29].

It was interesting that those with best C-peptide preservation, so-called good responders (GR), had higher GADA titers and higher proportion of IgG2, IgG3 and IgG4. We also observed a sustained re-call response to GAD65 in both CD4+ and CD8+ cells in the GR individuals, suggesting that the specific immunomodulation induced by the treatment was still persistent. Difference in the immune response at 30 months between GR and poor responders (PR) was in line with our previous findings at 15 months [21]. The increasing consensus on the heterogeneity of type 1 diabetes brings focus to the matter that, as in many other autoimmune diseases, some patients benefit from the treatments, while others do not [30, 31].

![Fig. 3 Clinical and immunological responses in patients \((n = 3)\) who received a late booster injection of GAD-alum. A Fasting and stimulated C-peptide (AUC), HbA1c, insulin dose and IDAAC expressed as percentages. B GADA titers \((U/ml)\) expressed as arbitrary units \((AUs,)\) and relative distribution of GADA IgG subclass. Frequencies of each subclass were calculated with respect to the combined sum of the AUs of the four subclasses in sample. C Cytokine secretion detected by Luminex in PBMCs supernatants after 7-day culture in the presence of GAD65 \((5 \mu g/ml)\) or medium alone. GAD65-induced cytokine secretion levels are given after subtraction of spontaneous secretion from each individual and expressed as pg/mL. D PBMCs proliferative responses to GAD65. Cells were cultured for 3 days with GAD65 \((5 \mu g/ml)\) or medium, and thereafter, cells were pulsed with \([3H]\) thymidine and harvested. Proliferation is expressed as stimulation index (SI) and calculated from the mean of triplicates in the presence of stimulus divided by the mean of triplicates with medium alone. SI scale started from 1 after dividing by the unstimulated value index \((SI \text{ unstimulated} = 1)\). Patient 5 (green line), patient 6 (red line) and patient 7 (blue line). Statistical analysis was not applied since individual values are shown.](image)
After the initial immune intervention, which was confirmed in the DIAGNODE-2 trial [24], the small size of the group included in this pilot trial precluded the analysis of HLA-associated clinical and immunological response. Still, the three individuals, who received a fourth intralymphatic injection at 31.5 months from baseline and increased in C-peptide, were all HLA DR3DQ2 positive, which might support the notion that carriers of this haplotype benefit clinically from GAD-alum booster injections. Here we also show that in addition to heterogeneity of the response based on HLA types, different immune response seems to be related to C-peptide preservation.

Even though we find C-peptide preservation and clinical response still after 30 months in many patients, the efficacy as well as the immune response has declined. Then the question arises whether the immune response and the C-peptide preservation can be enhanced by giving further booster dose of the autoantigen. In the DIAGNODE Extension study certainly, only three patients were included for safety reasons, being the first-in-human approach of administration of intra-lymphatic autoantigen with a booster dose given long time after the initial treatment (in this case 2.5 years). The small number of patients is of course a limitation, but it has to be considered that this is the first-in-human trial when autoantigen has been given in a booster dose. Afterward, it is easy to conclude that the treatment worked, and therefore, more patients could have been treated, but when the study was planned the consequences were completely unknown, and could have been deleterious. However, follow-up of these patients showed that administration of the booster dose was safe and tolerable with no adverse events. Furthermore, C-peptide secretion (AUC) seemed to increase almost 4 years after the initial immune intervention, which to our knowledge has never been shown before with any type of immune intervention. HbA1c, insulin requirement and IDAAC remained stable. The clinical results were accompanied by activation of the immune response as several cytokines were induced as part of immune response to GAD65. The results of this small DIAGNODE Extension trial will be the basis for coming studies when booster doses will be used in autoantigen treatment of type 1 diabetes and probably also other autoimmune diseases.

Development of treatment based on the administration of antigens directly into the lymph nodes is in an early stage [32]. Results from our first trial in humans with type 1 diabetes shows that this form of treatment seems to be a promising alternative for the disease [19–21], and these results have later been confirmed in the Phase II trial DIAGNODE-2 [24]. Our present results show some declining efficacy after 30 months, but the DIAGNODE Extension study suggests that repeated booster administration of GAD-alum might be a way to maintain the immunological and clinical effect. The efficacy of intralymphatic GAD-alum might be improved or at least maintained long term with repeated booster injections. These results are important and should be studied further.

**Supplementary Information** The online version contains supplementary material available at [https://doi.org/10.1007/s00592-022-01852-9](https://doi.org/10.1007/s00592-022-01852-9).

**Acknowledgements** We are very grateful to Joachim Davidson for skillful performance of the needle-guided lymph node injections and to research nurses Sofia Sjöberg, Endocrine Clinic, and to Anette Nilsson, Pediatric Clinic, University Hospital Linköping, for taking care of the patients. Ingela Johansson, Gosia Smolinska and Claudia Matzke are thanked for their skillful laboratory work. We would like to address the technical support from the flow cytometry core facility unit of the Faculty of Medicine and Health Sciences. The study has been generously supported by Barndiabetesfonden (Swedish Child Diabetes Foundation), Diabetesfonden (Swedish Diabetes Foundation) and an unrestricted grant from Diamyd Medical.

**Author’s contributions** JL had the idea of both DIAGNODE-1 and the DIAGNODE Extension study, designed both trials and wrote the protocols, recruited the patients and performed the clinical studies. FD and HB performed the laboratory experiments. SP-M and HB analyzed the data. SP-M, HB, RC and JL prepared the manuscript. RC conceived the laboratory study, designed data set and data analysis. JW recruited and followed adult patients. PA performed the analysis of GADA subclasses. All the authors read, reviewed and approved the final version of the manuscript. RC and JL are the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Funding** Open access funding provided by Linköping University. This work was supported by Barndiabetesfonden (Swedish Child Diabetes Foundation), Diabetesfonden (the Swedish Diabetes foundation) and an unrestricted grant from Diamyd Medical. The funders were not involved in the study design, collection, analysis and interpretation of data, the writing of this article or the decision to submit it for publication.

**Availability of data and material** Data may be available from the corresponding author on reasonable request after ethical approval.

**Declarations**

**Conflict of interest** No potential conflicts of interest relevant to this article exist. None of the authors in this article report any conflict of interest or competing interests.

**Ethical approval** DIAGNODE-1 was approved by the Research Ethics Committee, Linköping University, Sweden (Dnr 2014/153–31) and by the Medical Product Agency, Uppsala, Sweden, and DIAGNODE EXTENSION was also approved by the Research Ethics Committee, Linköping University, Sweden (Dnr 2018/57.32) and by the Medical Product Agency, Uppsala, Sweden.

**Consent to participate** All patients and caregivers when relevant gave their oral and written informed consent to participate in these studies.
Consent for publication All patients and caregivers when relevant gave their oral and written informed consent to publication of the results of these studies. All authors have approved publication.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J (1994) Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 330:15–18
2. M Lind, AM Svensson, M Kosiborod et al. (2014) Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 371: 1972–1982
3. Ludvigsson J, Heding L, Lieden G, Marner B, Lernmark A (1983) Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children. Br Med J (Clin Res Ed) 286:176–178
4. CR Stiller, A Laupacis, J Dupre et al. (1983) Cyclosporine for treatment of early type 1 diabetes: preliminary results. N Engl J Med 308:1226–1227
5. Coutant R, Landais P, Rosilio M et al (1998) Low dose lomnidine in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial. Diabetologia 41:1040–1046
6. Herold KC, Hagopian W, Auger JA et al (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346:1692–1698
7. Keymeulen B, Vandemeulebroecke E, Ziegler AG et al (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352:2598–2608
8. Sherry N, Hagopian W, Ludvigsson J et al (2011) Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 378:487–497
9. Hagopian W, Ferry RJ Jr, Sherry N et al (2013) Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomised, placebo-controlled Protege trial. Diabetes 62:3901–3908
10. Pescoitz MD, Greenbaum CJ, Krause-Steinrauf H et al (2009) Type 1 diabetes TrialNet anti CDSG. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 378:319–327
11. Ludvigsson J, Krisky D, Casas R et al (2012) GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 366:433–442
12. CA Beam, C MacCallum, KC Herold et al. (2017) Type 1 diabetes TrialNet Study G. GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis. Diabetologia 60:43–49
13. Johansen P, Haffner AC, Koch F et al (2005) Direct intrathyroidal injection of peptide vaccines enhances immunogenicity. Eur J Immunol 35:568–574
14. Mackensen A, Krause T, Blum U et al (1999) Homing of intravenously and intrathyroidally injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. Cancer Immunol Immunother 48:118–122
15. Ludvigsson J, Wahlberg J, Casas R (2017) Intrathyroidal injection of autotagien in type 1 diabetes. N Engl J Med 376:697–699
16. Casas R, Dietrich F, Barenilla H et al (2020) Glutamic acid decarboxylase antibody injection into lymph nodes: beta cell function and immune responses in recent onset type 1 diabetes patients. Front Immunol 11:564921
17. Hannelius U, Beam CA, Ludvigsson J (2020) Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes. Diabetologia 63:2177–2181
18. HB Mortensen, P Hougaard, P Swift Hvidoere study group on childhood diabetes et al. (2009) New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care. 32(8):1384–90. https://doi.org/10.2337/dc09-1384
19. Ludvigsson J, Sumnik Z, Pelikanova T et al (2021) Intrathyroidal glutamic acid decarboxylase with vitamin D supplementation in recent-onset type 1 diabetes: a double-blind, randomized, placebo-controlled phase Ib trial. Diabetes Care 44(7):1604–1612. https://doi.org/10.2337/dc21-0318
20. CJ Greenbaum, T Mandrup-Poulsen, PF McGee Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group et al. (2008) Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care. 31(10):1966–71. https://doi.org/10.2337/dc07-2451.
21. Cheramy M, Skoglund C, Johansson I, Ludvigsson J, Hampe CS, Casas R (2010) GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and hormonal response. Clin Immunol 137:31–40
22. Bonifacio E, Scipoli M, Kredel K, Fuchtenbusch M, Ziegler AG (1999) Early autoantibody responses in prediabetes are IgG1 dominated and suggest antigen-specific regulation. J Immunol 163:525–532
23. Axelson S, Cheramy M, Akerman L, Pihl M, Ludvigsson J, Casas R (2013) Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial. Diabetes Care 36:3418–3424
24. Wynn TA (2003) IL-13 effector functions. Annu Rev Immunol 21:425–456
25. Haller MJ, Gitelman SE, Gottlieb PA et al (2016) Anti-thymocyte globulin plus G-CSF combination therapy leads to sustained immunomodulatory and metabolic effects in a subset of responders with established type 1 diabetes. Diabetes 65:3765–3775
26. KC Herold, MD Pescoitz, P McGee et al. (2011) Type 1 diabetes TrialNet anti CDSG. Increased T cell proliferative responses to...
islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. J Immunol 187:1998–2005

32. J Ludvigsson J (2020) Autoantigen treatment in type 1 diabetes: unsolved questions on how to select autoantigen and administration route. Int J Mol Sci 21: 1598

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.